Treatment of unresectable primary liver cancer with intrahepatic fluorodeoxyuridine and mitomycin C through an implantable pump.

Published

Journal Article

Ten patients with unresectable primary liver cancer, eight of whom had elevated serum alpha-fetoprotein levels, were treated with intrahepatic fluorodeoxyuridine (FUDR) and mitomycin C administered through an implantable pump. Four patients had a partial response, and two had a minor response. The median survival from initiation of treatment was 14.5 months (range, 2 to 32 months), with patients receiving therapy for a median of 11.2 months. In general, the therapy was well tolerated; only one patient had treatment-related biliary sclerosis. In conclusion, the combination of intrahepatic FUDR and mitomycin C was an effective palliative regimen for unresectable primary liver cancer, even in the presence of elevated serum alpha-fetoprotein levels. Further studies are needed to confirm these findings and compare this regimen with other methods of treatment for hepatocellular carcinoma.

Full Text

Duke Authors

Cited Authors

  • Atiq, OT; Kemeny, N; Niedzwiecki, D; Botet, J

Published Date

  • February 15, 1992

Published In

Volume / Issue

  • 69 / 4

Start / End Page

  • 920 - 924

PubMed ID

  • 1370918

Pubmed Central ID

  • 1370918

International Standard Serial Number (ISSN)

  • 0008-543X

Digital Object Identifier (DOI)

  • 10.1002/1097-0142(19920215)69:4<920::aid-cncr2820690414>3.0.co;2-y

Language

  • eng

Conference Location

  • United States